Telesis Bio, Inc. (OTCMKTS:TBIO – Get Free Report) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 176 shares, a growth of 117.3% from the October 15th total of 81 shares. Based on an average daily trading volume, of 37 shares, the short-interest ratio is presently 4.8 days. Approximately 0.0% of the company’s shares are short sold.
Telesis Bio Price Performance
TBIO stock opened at $0.01 on Monday. The company has a market cap of $18,000.00, a price-to-earnings ratio of -0.00 and a beta of -14.02. The business has a fifty day simple moving average of $0.01 and a 200-day simple moving average of $0.03. Telesis Bio has a 52 week low of $0.00 and a 52 week high of $0.15.
About Telesis Bio
Telesis Bio, Inc. develops automated synthetic biology systems designed to help researchers create and test biological molecules more efficiently. Its technology is intended to streamline the design-build-test process by automating tasks that traditionally require multiple manual laboratory steps. The company’s primary products include the BioXp automated benchtop platforms and related consumables, software, and application-specific kits. These systems support the on-demand synthesis and assembly of DNA, messenger RNA and other biological constructs for applications such as gene and cell therapy research, vaccine development, protein engineering, diagnostics and synthetic biology.
Further Reading
- Five stocks we like better than Telesis Bio
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
